UT Health San Antonio Launches Groundbreaking Clinical Trial Investigating Rapamycin’s Role in Healthy Aging
In a significant stride toward understanding and potentially extending human health span, UT Health San Antonio, the academic health center affiliated with The University of Texas at San Antonio, has initiated a comprehensive multi-phase clinical trial probing the effects of rapamycin on aging. This ambitious study, financed by the National Institute on Aging, seeks to rigorously evaluate the optimal dosing, safety profiles, and long-term biological impacts of rapamycin, a drug increasingly spotlighted for its purported longevity benefits. By examining these dimensions in depth, the research aims to contribute foundational evidence that could transform clinical practices surrounding healthy aging.
Rapamycin, originally approved for immunosuppressive therapy in organ transplant recipients, has captured attention within both scientific and popular communities for its potential to modulate key aging pathways, particularly through inhibition of the mechanistic target of rapamycin (mTOR) signaling pathway. Despite widespread discourse labeling it a “longevity drug,” the current understanding of rapamycin’s effects is largely derived from animal models, necessitating careful and controlled human studies to elucidate its translational potential. The UT Health San Antonio trial is uniquely positioned to bridge this critical gap.
Leading this pioneering effort are researchers Ellen Kraig, PhD, from the Department of Cell Systems and Anatomy; Dean Kellogg Jr., MD, PhD, from the Division of Geriatrics, Gerontology and Palliative Medicine; and Brett Ginsburg, PhD, of the Department of Psychiatry and Behavioral Sciences, all based within the Joe R. and Teresa Lozano Long School of Medicine. This interdisciplinary team combines expertise in molecular biology, geriatrics, clinical pharmacology, and behavioral sciences to adopt a holistic approach to the study.
Central to the clinical investigation is a meticulously designed randomized, placebo-controlled trial enrolling roughly 84 older adult participants aged between 65 and 90 years, characterized by generally good health in non-smoking, independently living individuals without diabetes or usage of glucose-lowering medications. The participants will undergo a six-week course of rapamycin and everolimus administration, followed by a four-week observational period to monitor sustained biological responses and safety measures.
The study distinguishes itself by incorporating several sub-studies that delve into biological markers linked to aging and immune function, optimizing dosing strategies, and evaluating physiological outcomes. This nuanced approach reflects a scientific commitment to moving beyond anecdotal and preclinical speculation, focusing instead on data-driven, precision medicine principles. As Dr. Kraig emphasizes, establishing evidence-based understanding is paramount to discerning the true clinical viability of rapamycin in aging interventions.
Dr. Kellogg underscores the study’s goal to define the minimal effective dose necessary to elicit desired biological effects, an aspect critical to maximizing therapeutic benefits while minimizing potential adverse effects. This precise dosing inquiry is essential considering rapamycin’s complex pharmacodynamics, which involve modulation of mTOR complexes that regulate cell proliferation, metabolism, and autophagy—processes intricately tied to senescence and organismal lifespan.
The pharmacokinetic and pharmacodynamic dimensions of the trial are under the guidance of Brett Ginsburg, PhD, and his postdoctoral fellow Haidyn Stark, PhD. Together, they oversee comprehensive evaluations of how the drug is absorbed, metabolized, and exerts its effects on human physiology. Their expertise ensures that the molecular and clinical observations are cohesively integrated, reinforcing the scientific rigor of the endeavor.
Complementing these efforts is Wouter Koek, PhD, who spearheads the statistical analysis components, employing advanced biostatistical methodologies to interpret complex datasets generated from biochemical assays, immunological parameters, and clinical observations. This rigorous statistical framework ensures that the trial outcomes possess robust scientific validity and reproducibility.
Operational management of the clinical workflow rests with Dr. Tiffany Cortes and her clinical team at the Sam and Ann Barshop Institute for Longevity and Aging Studies Research Clinic. The clinical research nurses, including Gisela Ramirez, Katy Casique Cervantes, and Allison Stepanenko, coordinate participant engagement, adherence monitoring, and safety assessments, ensuring that clinical standards and ethical protocols are strictly maintained throughout the study duration.
Logistical and laboratory operations are efficiently handled by study coordinator Leslie Linehan and researcher Faizah Ahmmed, whose roles facilitate seamless integration between bench-side analyses and clinical data collection. This organizational backbone complements the scientific input from senior investigators such as Randy Strong, PhD, Adam Salmon, PhD, and Blake Rasmussen, PhD, who provide critical translational insights linking basic research discoveries to potential clinical applications.
While scattered reports have previously hinted at rapamycin’s promise in anti-aging interventions, the UT Health San Antonio trial represents one of the most systematic and rigorous efforts to dissect the clinical pharmacology and biological effects of this compound in an aging human population. By shining light on mechanisms such as autophagy enhancement, mitochondrial function improvement, and inflammation reduction—processes central to aging biology—this research can potentially recalibrate how science and medicine approach geriatric care.
The implications of this study extend beyond defining a single drug’s profile. Its findings could lay the groundwork for broader translational research aimed at harnessing molecular targets within the mTOR pathway to improve resilience and functional longevity in older adults. Furthermore, elucidating safety and dosing in a vulnerable population directly addresses the translational hurdles that often stall the clinical adoption of promising preclinical interventions.
Currently, researchers are recruiting healthy older adults who meet the study criteria to participate in this crucial investigation. Interested individuals, non-smokers between the ages of 65 and 90, who live independently and do not suffer from diabetes or require glucose-lowering medications, are encouraged to inquire about participation by contacting BCRU@uthscsa.edu or calling (210) 450-3333.
This robust clinical study may redefine our scientific understanding of aging therapeutics, merging the frontiers of molecular biology with clinical geriatrics, and ultimately influencing public health strategies aimed at improving the quality of life in later years. As the investigation unfolds, the scientific community and general public alike await insights that may transform aging from an inexorable decline into a manageable and modifiable phase of life.
Subject of Research: The role of rapamycin and everolimus in promoting healthy aging through precision dosing and biological effect evaluation in older adults.
Article Title: UT Health San Antonio Launches Groundbreaking Clinical Trial Investigating Rapamycin’s Role in Healthy Aging
News Publication Date: Not specified in the source content.
Web References: https://news.uthscsa.edu/large-rapamycin-clinical-trial-launches-at-ut-health-san-antonio/
Keywords: Rapamycin, healthy aging, clinical trial, precision dosing, mTOR pathway, older adults, longevity drug, pharmacokinetics, translational research, geriatrics, biological markers, FDA-approved drugs
